TABLE 3.
CASC11 expression in clinical samples of cancer (PTTA: pairs of tumor tissues and adjacent normal tissues, TNM: tumor-node-metastasis, T stage: tumor stage, OS: overall survival, DFS: disease-free survival, FIGO: international federation of gynecology and obstetrics, TCGA: the cancer genome atlas, GEO: gene expression omnibus).
| Cancer type | Samples | Expression of CASC11 (tumor vs. normal) | Kaplan-Meier analysis (impact of CASC11 up-regulation) | Association of high CASC11 expression with clinicopathologic parameters | References |
|---|---|---|---|---|---|
| Bladder cancer | Plasma samples from 89 patients and 62 controls | Up | _ | _ | Wang et al. (2019) |
| Cervical cancer | 50 PTTA | Up | Poorer survival | Tumor size, FIGO stage | Hsu et al. (2019) |
| Colorectal cancer | 27 PTTA | Up | _ | Tumor size, lymph-vascular invasion, lymph metastasis, T stage | Zhang et al. (2021) |
| 36 PTTA | Up (in 32 out of 36 pairs) | _ | Tumor size, serosal invasion, lymph metastasis, TNM stage | Zhang et al. (2016) | |
| Esophageal carcinoma | 45 PTTA | Up | Poorer survival | Pathological stage | Chen et al. (2019b) |
| Gastric cancer | 76 PTTA | Up | _ | Clinical stage, lymph node metastasis, distant metastasis | Su et al. (2019) |
| 80 PTTA | Up | _ | Tumor size, lymph node metastasis, TNM stage | Zhang et al. (2018) | |
| Glioma | 35 PTTA | Up | Poorer OS | Tumor size | Jin et al. (2019) |
| Hepatocellular carcinoma (HCC) | 72 PTTA | Up | Poorer OS | Tumor grade, metastasis | Chen et al. (2021) |
| 69 PTTA + patient blood samples | Up (tumor vs. normal and in blood samples: after carboplatin treatment vs. before treatment) | _ | _ | Liu et al. (2020) | |
| 68 PTTA | Up | Poorer OS | _ | Cheng et al. (2019) | |
| 76 PTTA | Up (tumor vs. normal and tumor tissues with metastasis vs. without metastasis) | Poorer OS | _ | Han et al. (2019) | |
| 78 PTTA + serum of 78 patients and 40 controls | Up | Poorer OS and DFS | Maximal tumor size | Song et al. (2020) | |
| Lung cancer | 30 PTTA | Up | _ | _ | Tong et al. (2019) |
| Neonatal neuroblastoma | 42 PTTA | Up | Poorer survival | _ | Yu et al. (2020) |
| Non-small-cell lung cancer | 40 PTTA | Up | Poorer survival | TNM stage, differentiation | Yan et al. (2019) |
| Ovarian cancer | 64 PTTA + plasma samples from 64 patients and 58 controls | Up | Poorer OS | _ | Cui et al. (2020) |
| Ovarian squamous cell carcinoma (OSCC) | Plasma samples from 72 patients and 56 controls | Up (patients vs. controls and in patients, after chemotherapy vs. before) | _ | _ | Shen et al. (2019) |
| Prostate cancer (PCa) | 66 PTTA + TCGA and GEO datasets | Up | _ | _ | Sun et al. (2022) |
| 29 tumor tissues and 5 normal samples | Up | _ | _ | Capik et al. (2021) | |
| Small cell lung cancer (SCLC) | Plasma samples from 71 patients and 54 controls | Up | Poorer OS | _ | Fu et al. (2019) |